Why the study?
To report the first known cases of sick sinus syndrome associated with anlotinib use in non-small cell lung cancer patients, highlighting the need for cardiac monitoring.
Does anlotinib induce sick sinus syndrome in patients with non-small cell lung cancer?
Does anlotinib induce sick sinus syndrome in patients with non-small cell lung cancer?
Anlotinib treatment in non-small cell lung cancer may be associated with the development of sick sinus syndrome, highlighting the need for cardiac monitoring.
BACKGROUND: This manuscript describes the first known cases of sick sinus syndrome (SSS) associated with the use of anlotinib in non-small cell lung cancer patients, highlighting the need for increased vigilance and cardiac monitoring. CASE SUMMARY: Two patients with non-small cell lung cancer developed SSS after 15 months and 5 months of anlotinib treatment, respectively, presenting with syncope and palpitations. Electrocardiogram confirmed SSS, and different treatment approaches were taken for each patient. One patient received a dual-chamber permanent pacemaker, while the other discontinued the medication and experienced symptom resolution. CONCLUSION: Anlotinib can induce SSS, suggesting that cardiac monitoring is crucial during anlotinib treatment. Individualized management strategies are necessary for affected individuals.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: